REGENXBIO Inc. (RGNX)

Market Cap	529.50M
Revenue (ttm)	86.73M
Net Income (ttm)	-260.15M
Shares Out	49.26M
EPS (ttm)	-5.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	481,493
Open	11.02
Previous Close	11.07
Day's Range	10.72 - 11.07
52-Week Range	10.72 - 28.80
Beta	1.34
Analysts	Strong Buy
Price Target	40.50 (+276.74%)
Earnings Date	Jul 31, 2024

About RGNX

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenn...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 17, 2015
• Employees: 344
• Stock Exchange: NASDAQ
• Ticker Symbol: RGNX

Financial Performance

In 2023, REGENXBIO's revenue was $90.24 million, a decrease of -19.94% compared to the previous year's $112.72 million. Losses were -$263.49 million, -6.00% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for RGNX stock is "Strong Buy." The 12-month stock price forecast is $40.5, which is an increase of 276.74% from the latest price.

Price Target

$40.5

(276.74% upside)

Analyst Consensus: Strong Buy